Physician profile
Regina Edelev
NPI 1891229654
$2,215.92
in general payments reported to CMS, 2019-2025
9 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $835 · 2023: $349 · 2024: $308 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $976.35 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $274.48 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $228.11 | 2024-2025 | Cobenfy |
| Abbvie INC. | $179.57 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $119.70 | 2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $113.03 | 2022-2024 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $100.80 | 2023 | Quviviq |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Edelev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.